<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00702234</url>
  </required_header>
  <id_info>
    <org_study_id>P05715</org_study_id>
    <secondary_id>2004-004967-30</secondary_id>
    <secondary_id>38829</secondary_id>
    <secondary_id>MK-8962-008</secondary_id>
    <nct_id>NCT00702234</nct_id>
  </id_info>
  <brief_title>Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05714 (Care Program)(P05715)</brief_title>
  <acronym>Care</acronym>
  <official_title>Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established After Controlled Ovarian Stimulation in Clinical Trial 38825 for Org 36286 (Corifollitropin Alfa)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to evaluate whether corifollitropin alfa (Org 36286) treatment
      for the induction of multifollicular growth in women undergoing controlled ovarian
      stimulation (COS) prior to in vitro fertilization (IVF) or intracytoplasmic sperm injection
      (ICSI) is safe for pregnant participants and their offspring. In addition, a primary efficacy
      variable, live birth rate, was evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a follow-up protocol to prospectively monitor pregnancy, delivery, and neonatal
      outcomes of women who were treated with corifollitropin alfa and became pregnant after fresh
      embryo transfer during the base study P05714 (NCT00696878). For this trial, no study specific
      assessments are required, but information as obtained in standard practice will be used.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2007</start_date>
  <completion_date type="Actual">January 15, 2010</completion_date>
  <primary_completion_date type="Actual">October 22, 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Women With Ongoing Pregnancy After a Corifollitropin Alfa COS Cycle in Base Study and ≥1 Live Born Infant During Follow-up (Live Birth Rate)</measure>
    <time_frame>Up to approximately 32 months after first dose of corifollitropin alfa in base study P05714 (NCT00696878)</time_frame>
    <description>The live birth rate was defined as the number of participants who had an ongoing pregnancy after a corifollitropin alfa COS cycle in base study P05714 (NCT00696878) and who had at least one live born infant during follow-up, divided by the number of participants treated in the base study. For this analysis, it was assumed that any participants with ongoing pregnancy after a COS cycle in base study who did not enroll in follow-up study P05715 had no live born infants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Expectant Mothers Experiencing Adverse Events (AEs)</measure>
    <time_frame>From approximately 10 weeks after fresh ET in base study P05714 up to birth of infant (up to approximately 6 months)</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Expectant Mothers Experiencing Serious AEs (SAEs)</measure>
    <time_frame>From approximately 10 weeks after fresh ET in base study P05714 up to birth of infant (up to approximately 6 months)</time_frame>
    <description>An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was a congenital anomaly/birth defect.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Live Born Infants Experiencing AEs</measure>
    <time_frame>Up to 12 weeks after birth</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Live Born Infants Experiencing SAEs</measure>
    <time_frame>Up to 12 weeks after birth</time_frame>
    <description>An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was a congenital anomaly/birth defect.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">268</enrollment>
  <condition>Pregnancy</condition>
  <condition>Neonates</condition>
  <arm_group>
    <arm_group_label>Women/Expectant Mothers - Corifollitropin Alfa 150 µg</arm_group_label>
    <description>In base study P05714 (NCT00696878), up to 3 COS cycles were performed, each including the following: A single injection of 150 µg corifollitropin alfa was administered on Day 2 or 3 of the menstrual cycle (Stimulation Day 1). Administration of Gonadotropin Releasing Hormone (GnRH) antagonist (0.25 mg/day) started on Stimulation Day 5 or 6 and continued through day of administration of recombinant Human Chorion Gonadotropin ([rec]hCG) (5,000-10,000 IU/250 µg). Daily dosing with Follicle Stimulating Hormone (FSH) (not to exceed 225 IU/day) began on Stimulation Day 8 and continued up to day of (rec)hCG administration. Progesterone was administered for luteal phase support. After COS cycles 1 and 2, Frozen-Thawed Embryo Transfer cycles (up to 3 after each COS cycle) could occur. Participants with confirmed pregnancy at least 10 weeks after fresh embryo transfer in the base study were eligible for this follow-up study. In this follow-up study P05715, no study drugs were administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Corifollitropin alfa</intervention_name>
    <description>Subcutaneous (SC) administration of corifollitropin alfa at a dose of 150 μg in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.</description>
    <arm_group_label>Women/Expectant Mothers - Corifollitropin Alfa 150 µg</arm_group_label>
    <other_name>Org 36286</other_name>
    <other_name>SCH 900962</other_name>
    <other_name>MK-8962</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GnRH antagonist</intervention_name>
    <description>SC administration of a GnRH antagonist at a dose of 0.25 mg/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.</description>
    <arm_group_label>Women/Expectant Mothers - Corifollitropin Alfa 150 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>(rec)hCG</intervention_name>
    <description>SC administration of (rec)hCG at a dose of 5,000-10,000 IU/250 µg in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.</description>
    <arm_group_label>Women/Expectant Mothers - Corifollitropin Alfa 150 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FSH</intervention_name>
    <description>SC administration of FSH at a dose not to exceed 225 IU/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.</description>
    <arm_group_label>Women/Expectant Mothers - Corifollitropin Alfa 150 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>Vaginal administration of progesterone at a dose of at least 600 mg/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.</description>
    <arm_group_label>Women/Expectant Mothers - Corifollitropin Alfa 150 µg</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women with an ongoing pregnancy at least 10 weeks after fresh embryo transfer in base study
        P05714 (NCT00696878) were enrolled in this trial.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants who participated in base study P05714 (NCT00696878) and received at least
             one dose of corifollitropin alfa in base study P05714;

          -  Ongoing pregnancy confirmed by ultrasound at least 10 weeks after a fresh embryo
             transfer in base study P05714;

          -  Able and willing to give written informed consent.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2008</study_first_submitted>
  <study_first_submitted_qc>June 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2008</study_first_posted>
  <results_first_submitted>April 9, 2015</results_first_submitted>
  <results_first_submitted_qc>April 9, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 27, 2015</results_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neonatal outcome</keyword>
  <keyword>Congenital malformations</keyword>
  <keyword>In-Vitro fertilization</keyword>
  <keyword>Controlled ovarian stimulation</keyword>
  <keyword>Follow-up</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=P05715&amp;kw=P05715&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Of 272 participants with ongoing pregnancy at 10 weeks after fresh embryo transfer (ET) in base study P05714 (NCT00696878), 268 enrolled in this follow-up study P05715. A participant could enter follow-up study without meeting formal definition for &quot;Completion&quot; of base study.</recruitment_details>
      <pre_assignment_details>To complete base study P05714 (NCT00696878), a participant must have embryo transfer in the 3rd Controlled Ovarian Stimulation (COS) cycle (Treatment Cycle 3). For this follow-up trial P05715, study completion for participant (expectant mother) or live born infant was defined as completion of infant follow-up visit at 4-12 weeks after delivery.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Women/Expectant Mothers - Corifollitropin Alfa 150 µg</title>
          <description>In base study P05714 (NCT00696878), up to 3 COS cycles were performed, each including the following treatments: A single injection of 150 µg corifollitropin alfa was administered on Day 2 or 3 of the menstrual cycle (Stimulation Day 1). Administration of Gonadotropin Releasing Hormone (GnRH) antagonist (0.25 mg/day) started on Stimulation Day 5 or 6 and continued through day of administration of recombinant Human Chorion Gonadotropin ([rec]hCG) (5,000-10,000 IU/250 µg). Daily dosing with Follicle Stimulating Hormone (FSH) (not to exceed 225 IU/day) began on Stimulation Day 8 and continued up to day of (rec)hCG administration. Progesterone was administered for luteal phase support. After COS cycles 1 and 2, Frozen-Thawed Embryo Transfer cycles (up to 3 after each COS cycle) could occur. Participants with confirmed pregnancy at least 10 weeks after fresh ET in the base study were eligible for this follow-up study. In this follow-up study P05715, no study drugs were administered.</description>
        </group>
        <group group_id="P2">
          <title>Fetuses Present at 10 Weeks After Fresh ET in Base Study</title>
          <description>This group includes fetuses associated with expectant mothers who were administered corifollitropin alfa in base study P05714 (NCT00696878) who were enrolled in this follow-up study P05715. The fetuses were present at 10 weeks after fresh ET in base study P05714 and/or at enrollment of the expectant mother in this follow-up study P05715.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Base Study (NCT00696878)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="682"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="178"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="504"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Follow-up Study: Expectant Mothers</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="268">A participant could enter follow-up study without meeting definition for &quot;Completion&quot; of base study</participants>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="246"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Follow-up Study: Fetuses/Infants</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="315">Fetuses present 10 weeks after fresh ET and/or at enrollment of expectant mother in follow-up study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Live Born Infants</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="304">Of the 11 that were not live born infants, outcome is known for 8 (fetus was lost) and unknown for 3</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="288">All 288 who completed were live born infants</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Individuals who participated in base study P05714 (NCT00696878) and received at least one dose of corifollitropin alfa, who had an ongoing pregnancy confirmed by ultrasound at least 10 weeks after fresh ET in base study P05714 and were able and willing to give written informed consent to be enrolled in the follow-up study.</population>
      <group_list>
        <group group_id="B1">
          <title>Expectant Mothers - Corifollitropin Alfa 150 µg</title>
          <description>In base study P05714 (NCT00696878), up to 3 COS cycles were performed, each including the following treatments: A single injection of 150 µg corifollitropin alfa was administered on Day 2 or 3 of the menstrual cycle (Stimulation Day 1). Administration of GnRH antagonist (0.25 mg/day) started on Stimulation Day 5 or 6 and continued through day of administration of (rec)hCG (5,000-10,000 IU/250 µg). Daily dosing with FSH (not to exceed 225 IU/day) began on Stimulation Day 8 and continued up to day of (rec)hCG administration. Progesterone was administered for luteal phase support. After COS cycles 1 and 2, Frozen-Thawed Embryo Transfer cycles (up to 3 after each COS cycle) could occur. Participants with confirmed pregnancy at least 10 weeks after fresh ET in the base study were eligible for this follow-up study. In this follow-up study P05715, no study drugs were administered.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="268"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.8" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="268"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Women With Ongoing Pregnancy After a Corifollitropin Alfa COS Cycle in Base Study and ≥1 Live Born Infant During Follow-up (Live Birth Rate)</title>
        <description>The live birth rate was defined as the number of participants who had an ongoing pregnancy after a corifollitropin alfa COS cycle in base study P05714 (NCT00696878) and who had at least one live born infant during follow-up, divided by the number of participants treated in the base study. For this analysis, it was assumed that any participants with ongoing pregnancy after a COS cycle in base study who did not enroll in follow-up study P05715 had no live born infants.</description>
        <time_frame>Up to approximately 32 months after first dose of corifollitropin alfa in base study P05714 (NCT00696878)</time_frame>
        <population>Participants administered corifollitropin alfa in base study P05714 (NCT00696878)</population>
        <group_list>
          <group group_id="O1">
            <title>Women - Corifollitropin Alfa 150 µg</title>
            <description>In base study P05714 (NCT00696878), up to 3 COS cycles were performed, each including the following treatments: A single injection of 150 µg corifollitropin alfa was administered on Day 2 or 3 of the menstrual cycle (Stimulation Day 1). Administration of GnRH antagonist (0.25 mg/day) started on Stimulation Day 5 or 6 and continued through day of administration of (rec)hCG (5,000-10,000 IU/250 µg). Daily dosing with FSH (not to exceed 225 IU/day) began on Stimulation Day 8 and continued up to day of (rec)hCG administration. Progesterone was administered for luteal phase support. After COS cycles 1 and 2, Frozen-Thawed Embryo Transfer cycles (up to 3 after each COS cycle) could occur. Participants with confirmed pregnancy at least 10 weeks after fresh ET in the base study were eligible for this follow-up study. In this follow-up study P05715, no study drugs were administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Women With Ongoing Pregnancy After a Corifollitropin Alfa COS Cycle in Base Study and ≥1 Live Born Infant During Follow-up (Live Birth Rate)</title>
          <description>The live birth rate was defined as the number of participants who had an ongoing pregnancy after a corifollitropin alfa COS cycle in base study P05714 (NCT00696878) and who had at least one live born infant during follow-up, divided by the number of participants treated in the base study. For this analysis, it was assumed that any participants with ongoing pregnancy after a COS cycle in base study who did not enroll in follow-up study P05715 had no live born infants.</description>
          <population>Participants administered corifollitropin alfa in base study P05714 (NCT00696878)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="682"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Expectant Mothers Experiencing Adverse Events (AEs)</title>
        <description>An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.</description>
        <time_frame>From approximately 10 weeks after fresh ET in base study P05714 up to birth of infant (up to approximately 6 months)</time_frame>
        <population>Follow-up safety analysis was performed on expectant mothers who received corifollitropin alfa in base study P05714 (NCT00696878) and who enrolled in the follow-up study.</population>
        <group_list>
          <group group_id="O1">
            <title>Expectant Mothers - Corifollitropin Alfa 150 µg</title>
            <description>In base study P05714 (NCT00696878), up to 3 COS cycles were performed, each including the following treatments: A single injection of 150 µg corifollitropin alfa was administered on Day 2 or 3 of the menstrual cycle (Stimulation Day 1). Administration of GnRH antagonist (0.25 mg/day) started on Stimulation Day 5 or 6 and continued through day of administration of (rec)hCG (5,000-10,000 IU/250 µg). Daily dosing with FSH (not to exceed 225 IU/day) began on Stimulation Day 8 and continued up to day of (rec)hCG administration. Progesterone was administered for luteal phase support. After COS cycles 1 and 2, Frozen-Thawed Embryo Transfer cycles (up to 3 after each COS cycle) could occur. Participants with confirmed pregnancy at least 10 weeks after fresh ET in the base study were eligible for this follow-up study. In this follow-up study P05715, no study drugs were administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Expectant Mothers Experiencing Adverse Events (AEs)</title>
          <description>An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.</description>
          <population>Follow-up safety analysis was performed on expectant mothers who received corifollitropin alfa in base study P05714 (NCT00696878) and who enrolled in the follow-up study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Expectant Mothers Experiencing Serious AEs (SAEs)</title>
        <description>An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was a congenital anomaly/birth defect.</description>
        <time_frame>From approximately 10 weeks after fresh ET in base study P05714 up to birth of infant (up to approximately 6 months)</time_frame>
        <population>Follow-up safety analysis was performed on expectant mothers who received corifollitropin alfa in base study P05714 (NCT00696878) and who enrolled in the follow-up study.</population>
        <group_list>
          <group group_id="O1">
            <title>Expectant Mothers - Corifollitropin Alfa 150 µg</title>
            <description>In base study P05714 (NCT00696878), up to 3 COS cycles were performed, each including the following treatments: A single injection of 150 µg corifollitropin alfa was administered on Day 2 or 3 of the menstrual cycle (Stimulation Day 1). Administration of GnRH antagonist (0.25 mg/day) started on Stimulation Day 5 or 6 and continued through day of administration of (rec)hCG (5,000-10,000 IU/250 µg). Daily dosing with FSH (not to exceed 225 IU/day) began on Stimulation Day 8 and continued up to day of (rec)hCG administration. Progesterone was administered for luteal phase support. After COS cycles 1 and 2, Frozen-Thawed Embryo Transfer cycles (up to 3 after each COS cycle) could occur. Participants with confirmed pregnancy at least 10 weeks after fresh ET in the base study were eligible for this follow-up study. In this follow-up study P05715, no study drugs were administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Expectant Mothers Experiencing Serious AEs (SAEs)</title>
          <description>An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was a congenital anomaly/birth defect.</description>
          <population>Follow-up safety analysis was performed on expectant mothers who received corifollitropin alfa in base study P05714 (NCT00696878) and who enrolled in the follow-up study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Live Born Infants Experiencing AEs</title>
        <description>An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.</description>
        <time_frame>Up to 12 weeks after birth</time_frame>
        <population>Follow-up safety analysis was performed on live born infants delivered by expectant mothers who received corifollitropin alfa in base study P05714 (NCT00696878) and who enrolled in the follow-up study.</population>
        <group_list>
          <group group_id="O1">
            <title>Live Born Infants</title>
            <description>This group includes infants born to mothers who were administered corifollitropin alfa in base study P05714 (NCT00696878) and who were enrolled in this follow-up study P05715. These infants, whose gestation outcome was live birth, are a subgroup of the total number of fetuses that were present at 10 weeks after fresh ET in base study P05714 and/or at enrollment of the expectant mother in this follow-up study P05715. Fetuses not born alive or with unknown outcome are not included in this reporting group.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Live Born Infants Experiencing AEs</title>
          <description>An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.</description>
          <population>Follow-up safety analysis was performed on live born infants delivered by expectant mothers who received corifollitropin alfa in base study P05714 (NCT00696878) and who enrolled in the follow-up study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Live Born Infants Experiencing SAEs</title>
        <description>An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was a congenital anomaly/birth defect.</description>
        <time_frame>Up to 12 weeks after birth</time_frame>
        <population>Follow-up safety analysis was performed on live born infants delivered by expectant mothers who received corifollitropin alfa in base study P05714 (NCT00696878) and who enrolled in the follow-up study.</population>
        <group_list>
          <group group_id="O1">
            <title>Live Born Infants</title>
            <description>This group includes infants born to mothers who were administered corifollitropin alfa in base study P05714 (NCT00696878) and who were enrolled in this follow-up study P05715. These infants, whose gestation outcome was live birth, are a subgroup of the total number of fetuses that were present at 10 weeks after fresh ET in base study P05714 and/or at enrollment of the expectant mother in this follow-up study P05715. Fetuses not born alive or with unknown outcome are not included in this reporting group.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Live Born Infants Experiencing SAEs</title>
          <description>An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was a congenital anomaly/birth defect.</description>
          <population>Follow-up safety analysis was performed on live born infants delivered by expectant mothers who received corifollitropin alfa in base study P05714 (NCT00696878) and who enrolled in the follow-up study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From approximately 10 weeks after fresh ET in base study P05714 (NCT00696878) up to 12 weeks after birth in current follow-up study (Up to approximately 9 months).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Expectant Mothers - Corifollitropin Alfa 150 µg</title>
          <description>In base study P05714 (NCT00696878), up to 3 COS cycles were performed, each including the following treatments: A single injection of 150 µg corifollitropin alfa was administered on Day 2 or 3 of the menstrual cycle (Stimulation Day 1). Administration of GnRH antagonist (0.25 mg/day) started on Stimulation Day 5 or 6 and continued through day of administration of (rec)hCG (5,000-10,000 IU/250 µg). Daily dosing with FSH (not to exceed 225 IU/day) began on Stimulation Day 8 and continued up to day of (rec)hCG administration. Progesterone was administered for luteal phase support. After COS cycles 1 and 2, Frozen-Thawed Embryo Transfer cycles (up to 3 after each COS cycle) could occur. Participants with confirmed pregnancy at least 10 weeks after fresh ET in the base study were eligible for this follow-up study. In this follow-up study P05715, no study drugs were administered.</description>
        </group>
        <group group_id="E2">
          <title>Fetuses Present at 10 Weeks After Fresh ET in Base Study</title>
          <description>This group includes fetuses associated with expectant mothers who were administered corifollitropin alfa in base study P05714 (NCT00696878) who were enrolled in this follow-up study P05715. The fetuses were present at 10 weeks after fresh ET in base study P05714 and/or at enrollment of the expectant mother in this follow-up study P05715.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="145" subjects_at_risk="268"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Anaemia neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation in newborn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia foetal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Bradycardia neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Foetal heart rate disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Ventricular hypokinesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Anal atresia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Ankyloglossia congenital</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Anomaly of external ear congenital</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Cleft palate</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Congenital cytomegalovirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Congenital diaphragmatic hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Congenital hand malformation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Congenital hydrocephalus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Congenital infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Congenital naevus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Congenital nose malformation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Congenital pulmonary artery anomaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Congenital pulmonary hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Congenital tongue anomaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Congenital torticollis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Cryptorchism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Cystic lymphangioma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Duodenal atresia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Dysmorphism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Factor IX deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Factor VIII deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Fallot's tetralogy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Haemangioma congenital</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Laryngomalacia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Oculoauriculovertebral dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Patent ductus arteriosus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pulmonary artery stenosis congenital</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pulmonary malformation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pulmonary sequestration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pyloric stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Renal dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Skull malformation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Solitary kidney</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Strabismus congenital</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Syndactyly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Talipes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Trisomy 18</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Trisomy 21</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>VACTERL syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Ventricular septal defect</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dacryostenosis acquired</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Retinopathy of prematurity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Cholestasis of pregnancy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Milk allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Endometritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Neonatal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Rotavirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Sepsis neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Uterine infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Perineal laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Amniotic fluid volume decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Foetal heart rate abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Foetal heart rate increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gestational diabetes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Delayed fontanelle closure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Torticollis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Abortion threatened</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Antepartum haemorrhage</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Arrested labour</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Breech presentation</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Cephalo-pelvic disproportion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Cervical incompetence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Delayed delivery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Failed induction of labour</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Foetal acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Foetal distress syndrome</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Foetal growth retardation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Foetal macrosomia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Foetal malposition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Foetal malpresentation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>HELLP syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>High risk pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Intra-uterine death</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Jaundice neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Meconium in amniotic fluid</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Multiple pregnancy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Oligohydramnios</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Placenta praevia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Postpartum haemorrhage</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pregnancy induced hypertension</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Premature baby</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="50" subjects_affected="50" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Premature labour</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Premature rupture of membranes</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Premature separation of placenta</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Previous caesarean section</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Prolonged labour</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Retained placenta or membranes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Small for dates baby</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Threatened labour</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Transverse presentation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Twin pregnancy</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Umbilical cord abnormality</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Umbilical cord prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Uterine contractions abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Perineal fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Vaginal laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthmatic crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Immature respiratory system</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Infantile apnoeic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Neonatal asphyxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Neonatal aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Neonatal respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cafe au lait spots</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Caesarean section</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Selective abortion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publications must be based on data validated and released by the Sponsor. Any scientific paper, presentation, or other communication concerning the study must first be submitted to the Sponsor, at least 6 weeks prior to estimated publication or presentation, for written consent. Sponsor has the right to make its consent conditional upon proper representation of the interpretation of both the Sponsor and the Investigator in the discussion of the data in such communications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

